The study compared guaiac-based fecal occult blood test or fecal immunochemical test annually, fecal DNA every three years, flexibly sigmoidoscopy or computed tomographic colonography every five years and colonoscopy every 10 years. Researchers gathered outcome measures, including lifetime costs, number of cancers detected, incremental cost-utility ratios and more.
Researchers concluded fecal immunochemical test should be prioritized for colorectal screening in patients.
Read the study about the cost analysis of colorectal cancer screening modalities.
Read other coverage about colorectal screening:
– Researchers Investigate Possible Association of Inflammatory Markers and NSAIDs With CRC
– Researchers Revisit Surveillance Colonoscopy Utilization
– 4 Steps to Increase Screening Colonoscopy Cases
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
